早期乳腺癌术后外照射加速部分乳腺照射的早期与中期治疗结局
前瞻性评估早期乳腺癌患者术后加速部分乳腺照射(APBI)的早期和中期结局。纳入标准依据ASTRO循证共识声明,处方剂量26至28 Gy分5次连续5天完成。175例患者中位随访45个月,4年乳腺内复发率2.5%,4年总生存率97.1%,耐受性良好。
要点
- APBI处方26至28 Gy分5次连续5天,急性毒性低,2周时69%为0级、26%为1级、5%为2级。
- 患者报告美容结局优良率在各随访点达97.9%至100%,未发生3级及以上毒性。
- 4年乳腺内复发率2.5%,4年总生存率97.1%、癌症特异生存率99.4%、无病生存率95.3%。
核心结论
- 在严格选择的早期乳腺癌患者中,26至28 Gy分5次一周内完成的APBI显示出良好的早期和中期治疗耐受性和疾病控制。
- APBI受到患者高度认可且高效,对繁忙中心是额外优势。
研究设计与样本
- 前瞻性评估早期乳腺癌患者术后外照射APBI的早期和中期结局。
- 纳入标准依据美国放射肿瘤学会(ASTRO)APBI循证共识声明制定。
- 2017年2月至2020年1月纳入175例保乳手术患者,平均年龄65.7岁(范围46至88岁)。
- 处方剂量为26至28 Gy分5次在连续5天内完成。
主要发现
- 13%患者诊断为原位癌,55%、35%、37%分别为T1a/b/c期,10%为T2期。
- 计划靶区(PTV)平均体积119 cc(范围45至465),平均PTV与全乳体积比21%(7%至53%)。
- 平均随访42个月(中位45,范围0至67);截至2023年3月记录5例同侧乳腺复发(1例PTV边缘,4例野外)和5例远处复发。
- 4年乳腺内复发率2.5%;8例死亡,其中2例死于疾病;4年总生存率97.1%、癌症特异生存率99.4%、无病生存率95.3%。
- 2周急性毒性0、1、2级分别为69%、26%、5%;2级纤维化各随访点分别为3%、2%、2%、0%、0%,2级萎缩分别为1%、1%、0%、0%、0%,无2级皮肤毛细血管扩张或乳腺水肿,无3级及以上毒性。
关键数值与推荐
- 处方剂量26至28 Gy分5次连续5天。
- 纳入标准依据ASTRO APBI循证共识声明。
- 患者报告美容结局优良率在1、2、3、4、5年分别为97.9%、98.5%、98.1%、98.6%、100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively evaluate early and intermediate outcome after accelerated partial breast irradiation (APBI) in patients early-with stage breast cancer. METHODS AND MATERIALS: Inclusion criteria were defined according to the APBI American Society for Radiation Oncology's ASTRO Evidence-Based Consensus Statement. The prescribed dose was 26 to 28 Gy in 5 fractions on 5 consecutive days. Regular follow-up visits with objective and subjective evaluation of treatment tolerance were performed after 0 and 2 weeks, 6 months, and at annual intervals. RESULTS: Between February 2017 and January 2020, 175 patients with breast conserving surgery met the inclusion criteria for APBI. Mean age was 65.7 years (range, 46-88). Thirteen percent of patients received a diagnosis with carcinoma in situ, 55%, 35%, and 37% with T1a/b/c, and 10% with T2 stages, respectively. The mean volume of planning target volume (PTV) was 119 cc (range, 45-465), the ratio of mean PTV: whole breast volume ratio was 21% (7%-53%). Mean follow-up was 42 months (median, 45, range, 0-67). Acute toxicity after 2 weeks was low with 69%, 26%, and 5% grade 0, 1, and 2. In addition, 1-, 2-, 3-, 4-, and 5-year follow-up data were available from 146, 134, 107, 73, and 25 patients. Patient-reported cosmetic outcomes were assessed excellent or good in 97.9%, 98.5%, 98.1%, 98.6%, and 100%. Regarding grade 2 toxicities, as by now 3%, 2%, 2%, 0%, and 0% G2 fibrosis, 1%, 1%, 0%, 0%, and 0% G2 atrophy, no G2 skin telangiectasia or breast edema occurred. So far, none of the patients have experienced G3 toxicity or higher. The remaining patients had grade 0 or 1 toxicity only. Five ipsilateral breast recurrences (1 marginally to PTV, 4 out-of-field) and 5 distant recurrences were recorded by March 2023. The 4-year in-breast recurrence rate was 2.5%. Eight patients died, with 2 of them from disease. For all patients, the 4-year overall, cancer specific and disease-free survival rates were 97.1%, 99.4%, and 95.3%, respectively. CONCLUSIONS: We showed high early- and intermediate-term treatment tolerance and disease control of APBI using 26 to 28 Gy in five fractions in one week in carefully selected patients with early breast cancer. APBI is highly appreciated by patients and efficient, as an additional advantage for busy centers.
引用
- Stenger-Weisser A, Unterkirhere O, Glanzmann C, et al. Early and Intermediate Treatment Outcome After Postoperative External Beam Accelerated Partial Breast Irradiation in Patients With Early-Stage Breast Cancer. Pract Radiat Oncol. 2023. PMID: 37925101. doi:10.1016/j.prro.2023.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。